Quest Diagnostics Incorporated (DGX) financial statements and ratios from SEC XBRL: revenue $11.6B (TTM), net margin 9.0%, revenue growth 10.2% YoY, P/E 25.4. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $11.04B |
| Revenue (TTM) | $11.6B |
| Net Margin | 9.0% |
| Operating Margin (TTM) | 14.1% |
| Net Debt / EBITDA | 2.3 |
| Revenue Growth (YoY) | 10.2% |
| EPS Growth (YoY) | 14.7% |
| FCF Growth (YoY) | 5.3% |
| P/E Ratio | 25.4 |
| EV / EBITDA | 14.5 |
| Price / Book | 3.45 |
| Price / Sales | 2.33 |
| FCF Yield | 5.0% |
| Altman Z-Score | 3.65 (safe) |
| Piotroski F-Score | 8/9 |
| Piotroski checks passed | 8 of 9 |
| Industry P/E (Healthcare Services) | 25.4 |
| Sector P/E (Healthcare) | 21.9 |
DGX overview · DGX earnings · DGX KPIs · DGX documents · DGX ownership · DGX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.